In order to expand the presence of innovative drugs in Ukraine, it is necessary to use the technology transfer mechanism, President of the Association of Manufacturers of Medications of Ukraine (AMMU) Petro Bahriy believes.
“The localization of production makes it possible to bring such products to the Ukrainian market. Roche had localized drugs protected by a patent. There is another example, when JSC Farmak, thanks to a technology transfer, began production of insulin for Eli Lilly. It was an innovative medicine. The project is still being developed at Farmak and is considered very successful. They sell insulin in other markets and the country only benefits from this,” he said in an exclusive interview with Interfax-Ukraine.
At the same time, Bahriy stressed that for the implementation of technology transfer projects, a “message” is needed from the state that it is ready to buy effective innovative drugs.
“In order for original innovative Ukrainian products to appear, we need to invest in science and development, and this is very expensive. Technology transfer is the best mechanism, but cooperation with transnational corporations is impossible in a situation where the state declares that we buy the cheapest,” he said.
